Related Experiment Videos
Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism
J A Braddock1, D B Church, I D Robertson
1Faculty of Veterinary Science, The University of Sydney, New South Wales, 2006.
Australian Veterinary Journal
|April 15, 2004
Summary
Trilostane effectively treated pituitary-dependent hyperadrenocorticism in dogs. This study found trilostane safe and effective, with most dogs responding well to treatment for Cushing's disease.
Area of Science:
- Veterinary Medicine
- Endocrinology
- Pharmacology
Background:
- Pituitary-dependent hyperadrenocorticism (PDH) is a common endocrine disorder in dogs.
- Effective and safe treatment options for PDH are crucial for improving canine health.
- Trilostane, an inhibitor of steroidogenesis, has emerged as a potential therapeutic agent.
Purpose of the Study:
- To assess the efficacy and safety of trilostane in treating dogs diagnosed with PDH.
- To determine optimal dosing and monitoring strategies for trilostane therapy.
- To evaluate trilostane's impact on clinical signs and biochemical parameters in affected dogs.
Main Methods:
- A prospective clinical trial was conducted involving 30 client-owned dogs with PDH.
- Dogs were treated with trilostane (once daily) and monitored over time.
- Monitoring included clinical examinations, tetracosactrin stimulation tests, and urinary corticoid:creatinine ratio measurements.
Main Results:
- Trilostane successfully controlled PDH in 29 out of 30 dogs.
- The median effective dose was 16.7 mg/kg once daily.
- Most dogs showed initial sensitivity, requiring dose adjustments for stable long-term control.
Conclusions:
- Trilostane is a safe and effective treatment for canine pituitary-dependent hyperadrenocorticism.
- The urinary corticoid:creatinine ratio is a useful tool for monitoring treatment efficacy.
- Long-term treatment may require dose adjustments to prevent iatrogenic hypoadrenocorticism.